
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc's positive outlook is supported by significant revenue growth, with Q3 revenue reported at $18,942, reflecting a 31% increase year-over-year, driven by an impressive 89% rise in Nociscan report volumes. The company's ongoing momentum is further evidenced by the successful enrollment of commercial agreements with notable healthcare institutions, which is anticipated to enhance the adoption of their Nociscan platform. Additionally, Aclarion's proactive investment in sales and marketing, evidenced by a 172% year-over-year increase in related expenses, indicates a strategic commitment to expanding market presence and supporting clinical trial initiatives.
Bears say
Aclarion Inc faces a challenging financial outlook primarily due to slower-than-expected market traction with both surgeons and payers, which jeopardizes the growth potential of its Nociscan product. The company has consistently revised its FY25 earnings per share (EPS) estimates downward, with projections now reaching as low as $(15.13) due to mounting operating expenses that exceed earlier forecasts. Additionally, significant risks related to liquidity, regulatory approvals, reimbursement issues, and competitive pressures further complicate the company’s ability to achieve its commercial objectives and stabilize financial performance.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares